NCT04931368View on ClinicalTrials.gov

OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

326

Participants

Timeline

Start Date

June 7, 2021

Primary Completion Date

February 29, 2028

Study Completion Date

November 30, 2028

Conditions
Primary Central Nervous System Lymphoma
Interventions
DRUG

Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix

De-escalated induction treatment with R/HD-MTX and two courses of MATRix

DRUG

Control intervention: four courses of MATRix

Patients receive four courses of MATRix as induction treatment.

Trial Locations (1)

70174

RECRUITING

Klinikum Stuttgart, Stuttgart

All Listed Sponsors
collaborator

German Federal Ministry of Education and Research

OTHER_GOV

collaborator

University Hospital Freiburg

OTHER

lead

Klinikum Stuttgart

OTHER

NCT04931368 - OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma | Biotech Hunter | Biotech Hunter